Allogene Therapeutics(ALLO)
Focus: Allogene Therapeutics is a public biotechnology company specializing in allogeneic CAR-T cell therapy for hematologic malignancies, autoimmune diseases, and solid tumors. The company operates at mid-cap biotech scale with 1,001-5,000 employees.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
18+8 this month
Growing — net +8 jobs in 30d
12 jobs added vs 4 removed. Steady team buildout.
Should You Work at Allogene Therapeutics?
AI assessmentCompelling for cell therapy specialists seeking cutting-edge science, but requires tolerance for pre-revenue biotech risk and potential restructuring as pipeline advances.
Why Work Here
- Leading expertise in allogeneic CAR-T—a differentiated modality with significant unmet need across oncology and autoimmune disease
- Diverse pipeline spanning 9+ active trials across hematologic malignancies, solid tumors, and SLE with multiple Phase 1/2 programs advancing
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
13 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22K
Pipeline & Clinical Trials
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Hematologic MalignanciesClinical Trials (1)
NCT06925685Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
N/AHelp build intelligence for Allogene Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.